A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

By Akin Akinc, A. Zumbuehl, Michael S. Goldberg, Elizaveta S. Leshchiner, V. Busini, Naushad Hossain, Sergio Bacallado, David N. Nguyen, Jason Fuller, R. Álvarez and 22 more. Nature Biotechnology, 2008

1,181 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0b61f1742db03583c03ba25f874c9e3193e4ac51

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Therapeutic siRNA silencing in inflammatory monocytes (2011, methodology): “For silencing CD45, we used a duplex with the following sequence: 5′-cuGGcuGAAuuucAGAGcAdTsdT-3′ (sense), 5′-UGCUCUGAAAUUcAGCcAGdTsdT-3′ (antisense), as published previousl”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, methodology): “To overcomes this, we can use certain methods that can test numerous nano-formulation and by selective iterations selecting a single optimized formulation [190-192].”
Nanoparticles in the clinic (2016, methodology): “Recent research efforts have described methods to test numerous nanoparticle formulations for specific biological functions or in vitro release profiles, and through selective iterations arriving at a single optimized formulation for a single specific function (Figure 4a).(91,127,128) The most advan”
Lipid-like materials for low-dose, in vivo gene silencing (2010, methodology): “in vivo gene silencing Kevin T. Lovea,1, Kerry P. Mahonb,1, Christopher G. Levinsb,c, Kathryn A. Whiteheadb, William Querbesd, J. Robert Dorkind, June Qind, William Cantleyd, Liu Liang Qind, Timothy Racied, Maria Frank-Kamenetskyd, Ka Ning Yipa, Rene Alvarezd, Dinah W. Y. Sahd, Antonin de Fougerolle”
RNA interference in the clinic: challenges and future directions (2010, background): “A fairly new class of lipid-like compounds that is composed of amino-alkylacrylate and amino-acrylamide materials has been termed lipidoids; and these lipidoids have proved safe and well-tolerated in mice and cynomolgus primate”
Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “, 2005), lipids and liposomes (Akinc et al., 2008; Wu and McMillan, 2009), antibody (Ab)-fusion molecules [Ab-protamine (Peer et al.”